RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Mid-Regional Pro-Adrenomedullin Test Predicts 90-Day Mortality after Heart Failure
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 8
IS 8
SP 19
OP 20
DO 10.1177/155989770900800811
UL http://mdc.sagepub.com/content/8/8/19.abstract
AB A novel biomarker, mid-regional pro-adrenomedullin (MR-proADM), has been shown to predict mortality among patients with heart failure better than the established biomarkers for prognosis that currently are available. MR-proADM was compared with brain natriuretic peptide (BNP) and NT-proBNP (a biologic fragment associated with BNP) in the BACH trial [NCT00537628], which is the largest biomarker study to be done in the setting of suspected heart failure.